The annotated case report describes the case of a patient with ulcerative colitis who was successfully treated with infliximab at the beginning of disease due to failure of conventional therapy. For a long-term remission of UC, it was decided to end biological therapy during the third trimester of pregnancy.
For the relapse of UC after the delivery, the initiation of vedolizumab therapy was indicated, after which a remission of UC was achieved, and therefore VDZ maintenance treatment was continued in the following course. A new pregnancy occurred on this therapy, which developed without complications to the indicated treatment.
This thesis evaluates the benefits and possible risks of biological treatment during pregnancy.